512 results on '"Taccetti G"'
Search Results
2. WS09.02 Biomarkers for monitoring the effect of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis
3. P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study
4. P061 Effect of elexacaftor/tezacaftor/ivacaftor on inflammatory parameters and bacterial respiratory cultures in children and adolescents with cystic fibrosis: a retrospective, dual-center cohort study
5. P221 Airways viral infections in children and adults with cystic fibrosis
6. A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials
7. Risk of CFTR-related disorders and cystic fibrosis in an Italian cohort of CRMS/CFSPID subjects in preschool and school age
8. 71 No SARS-CoV-2 viral upper and lower airways infection in cystic fibrosis: evaluation of clinical outcomes
9. 611 Quantity-not-sufficient sweat test in children undergoing newborn screening for cystic fibrosis
10. 713 Isolation of non-aeruginosa Pseudomonas from cystic fibrosis airways: a consequence of elexacaftor-tezacaftor-ivacaftor therapy? Results of a multicenter study
11. P193 Lung clearance index in asymptomatic CRMS/CFSPID infants progressed to a diagnosis of cystic fibrosis for pathological sweat test: a monocentric prospective experience
12. P004 Clinical consequences and functional impact of the rare S737F CFTR variant
13. EPS9.10 Could anti-Pseudomonas aeruginosa antibodies be a useful marker in monitoring the effect of ETI treatment on airways’ microbiology in cystic fibrosis (CF)?
14. WS13.03 Microbiology of upper and lower airways of cystic fibrosis (CF) patients in stable conditions and in lung transplant patients
15. Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis
16. Unilateral temporary diaphragmatic paralysis secondary to bronchial artery embolization in a girl with cystic fibrosis and massive hemoptysis: a case report
17. 569 Use of anti-Pseudomonas aeruginosa antibodies and characterization of P. aeruginosa isolates for early antibiotic treatment monitoring
18. 490 Evaluation of the BioFire FilmArray Pneumonia Panel Plus for diagnosis of lower respiratory tract infections in people with cystic fibrosis who have undergone lung transplantation
19. 493 Bacterial and viral upper and lower airways infection in people with cystic fibrosis in stable condition
20. Evidence of transmission of a Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus clone: a family affair
21. P142 Upper and lower airways microbiological status in cystic fibrosis patients in stable conditions and in lung transplant patients
22. P164 Nutritional status and circulating levels of fat-soluble vitamins in cystic fibrosis: cross-sectional analysis and effect of elexacaftor/tezacaftor/ivacaftor
23. P146 Microbiological diagnostic procedures for respiratory cystic fibrosis samples: results of a survey in Italian laboratories
24. P118 Airways respiratory viral infections in cystic fibrosis
25. Clinical characteristics and outcome of SARS –CoV-2 infection in patients with cystic fibrosis managed at home
26. [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020]
27. Kawasaki syndrome: the Florentine experience
28. Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: A national overview
29. Sex Ratio at Birth among Chinese Babies Born in Italy Is Lower than in China
30. Italian cystic fibrosis registry (ICFR): Report 2017-2018
31. P262 Respiratory microbiological patterns and comparison in patients with CFTR-related disorders, cystic fibrosis and non-cystic fibrosis bronchiectasis
32. P231 Monitoring of respiratory tract infections of cystic fibrosis transplanted patients by means of a multiplex PCR assay
33. EPS7.01 Cystic fibrosis screen positive inconclusive diagnosis (CFSPID): an Italian multicentre survey evaluating progression to definitive diagnoses
34. P037 Elexacaftor/tezacaftor/ivacaftor improve lung disease in patients with advanced cystic fibrosis homozygous for the F508del mutation
35. WS12.3 Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in cystic fibrosis severe patients with the F508del/minimal function genotype
36. P163 Effects of the SARS-CoV-2 pandemic on attendance at the cystic fibrosis centre and the definition of the microbiological status of cystic fibrosis patients in Tuscany
37. LOW PREVALENCE OF CHRONIC PSEUDOMONAS AERUGINOSA INFECTION IN CYSTIC FIBROSIS PATIENTS DIAGNOSED BY NEWBORN SCREENING (NBS) AND TREATED WITH EARLY ERADICATION TREATMENT: 19 YEARS OF EXPERIENCE: 443
38. COMPARATIVE IN VITRO ACTIVITY OF TEMOCILLIN AGAINST BURKHOLDERIA CEPACIA COMPLEX MEMBERS AND BURKHOLDERIA GLADIOLI: 319
39. IN VITRO ACTIVITY OF TEMOCILLIN ON MULTIRESISTANT P. AERUGINOSA ISOLATED FROM CYSTIC FIBROSIS PATIENTS: 324
40. GENETIC BACKGROUND OF MRSA COLLECTED FROM CYSTIC FIBROSIS (CF) PATIENTS VERSUS MRSA COLLECTED FROM INTENSIVE CARE UNIT (ICU) PATIENTS: DOES ANY DIFFERENCE EXIST?: 318
41. EVALUATION OF ANTIBODY TITER ANTI-P. AERUGINOSA IN PATIENTS UNDERGOING ERADICATION THERAPY: 231
42. PANCREATIC STATUS AND FEV1 DECLINE: THE CASE OF AN ITALIAN REGION: 361
43. MOLECULAR ANALYSIS OF MRSA ISOLATED FROM PERSISTENT INFECTION IN CYSTIC FIBROSIS ITALIAN PATIENTS: 302
44. PSEUDOMONAS AERUGINOSA ERADICATION IN CYSTIC FIBROSIS: FINAL RESULTS OF A RANDOMIZED MULTICENTER STUDY OF TWO DIFFERENT EARLY ANTIBIOTIC TREATMENT PROTOCOLS: 291
45. PSEUDOMONAS AERUGINOSA MICROBIOLOGICAL STATUS AND EMERGENCE OF OTHER PATHOGENS AFTER EARLY ERADICATION TREATMENT IN CYSTIC FIBROSIS: A POST-TRIAL FOLLOW-UP: 292
46. P018 Symptoms at diagnosis and genotype of false negatives (FNs) in newborn screening (NBS) in Tuscany: experience over 26 years
47. A critical review of definitions used to describe Pseudomonas aeruginosa microbiological status in patients with cystic fibrosis for application in clinical trials
48. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
49. COMMUNITY-ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (CA-MRSA) DIFFUSION IN A POPULATION AT RISK OF HOSPITAL STRAIN ACQUISITION: OP11
50. Volumetric Bone Density and Geometry Assessed by Peripheral Quantitative Computed Tomography in Uremic Patients on Maintenance Hemodialysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.